[go: up one dir, main page]

MX2010005858A - Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38. - Google Patents

Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.

Info

Publication number
MX2010005858A
MX2010005858A MX2010005858A MX2010005858A MX2010005858A MX 2010005858 A MX2010005858 A MX 2010005858A MX 2010005858 A MX2010005858 A MX 2010005858A MX 2010005858 A MX2010005858 A MX 2010005858A MX 2010005858 A MX2010005858 A MX 2010005858A
Authority
MX
Mexico
Prior art keywords
sadv
simian
subfamily
adenoviruses
adenoviruses sadv
Prior art date
Application number
MX2010005858A
Other languages
English (en)
Inventor
Soumitra Roy
James M Wilson
Luc H Vandenberghe
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2010005858A publication Critical patent/MX2010005858A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un vector recombinante comprende secuencias de adenovirus simiano SAdV-39, -25.2, -26, -30, -37 y -38 y un gen heterólogo bajo el control de secuencias reguladoras; también se describe una línea de células que expresa gen(es) de adenovirus simianos SAdV-39, -25.2, -26, -30, -37 y -383; también se proveen métodos para usar los vectores y líneas de células.
MX2010005858A 2007-11-28 2008-11-24 Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38. MX2010005858A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US453207P 2007-11-28 2007-11-28
US449907P 2007-11-28 2007-11-28
US454107P 2007-11-28 2007-11-28
US446407P 2007-11-28 2007-11-28
US450707P 2007-11-28 2007-11-28
US446107P 2007-11-28 2007-11-28
PCT/US2008/013066 WO2009073104A2 (en) 2007-11-28 2008-11-24 Simian e adenoviruses sadv-39, -25. 2, -26, -30, -37, and -38

Publications (1)

Publication Number Publication Date
MX2010005858A true MX2010005858A (es) 2010-06-11

Family

ID=40380705

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014000110A MX347246B (es) 2007-11-28 2008-11-24 Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.
MX2010005858A MX2010005858A (es) 2007-11-28 2008-11-24 Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014000110A MX347246B (es) 2007-11-28 2008-11-24 Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.

Country Status (20)

Country Link
US (3) US8685387B2 (es)
EP (2) EP2220241B1 (es)
JP (3) JP5740158B2 (es)
KR (3) KR101614364B1 (es)
CN (1) CN101883858B (es)
AU (1) AU2008331906B2 (es)
BR (1) BRPI0819783A2 (es)
CA (2) CA2964396A1 (es)
CY (1) CY1118351T1 (es)
DK (1) DK2220241T3 (es)
ES (1) ES2607029T3 (es)
HR (1) HRP20161573T1 (es)
HU (1) HUE032142T2 (es)
LT (1) LT2220241T (es)
MX (2) MX347246B (es)
PL (1) PL2220241T3 (es)
PT (1) PT2220241T (es)
SG (1) SG10201604001XA (es)
SI (1) SI2220241T1 (es)
WO (1) WO2009073104A2 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2220241T3 (pl) * 2007-11-28 2017-06-30 The Trustees Of The University Of Pennsylvania Adenowirus zawierający kapsydowe białko heksonu SAdV-39 małpiego adenowirusa E oraz jego zastosowanie
BRPI0819774A2 (pt) 2007-11-28 2014-10-14 Univ Pennsylvania Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
US8524219B2 (en) 2007-11-28 2013-09-03 The Trustees Of The University Of Pennsylvania Simian subfamily B adenoviruses SAdV-28, -27, -29, -32, -33, and -35 and uses thereof
EP2325298B1 (en) 2008-03-04 2016-10-05 The Trustees Of The University Of Pennsylvania SIMIAN ADENOVIRUSES SAdV-36, -42.1, -42.2, AND -44 AND USES THEREOF
JP5809978B2 (ja) 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−４３、−４５、−４６、−４７、−４８、−４９および−５０ならびにそれらの用途
JP5882741B2 (ja) 2009-02-02 2016-03-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
EP2435559A1 (en) 2009-05-29 2012-04-04 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
WO2011057248A2 (en) 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use
WO2011057254A2 (en) * 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
AU2011332025B2 (en) * 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
EP2651439B1 (en) * 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
WO2012154994A2 (en) * 2011-05-10 2012-11-15 The Regents Of The University Of Californa A novel adenovirus isolated from titi monkeys
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
US9217159B2 (en) * 2012-05-18 2015-12-22 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof
KR102115630B1 (ko) * 2012-08-03 2020-05-27 세다르스-신나이 메디칼 센터 약물 전달 단백질의 수송-증진 돌연변이체의 단리
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
EP4043021A3 (en) 2014-09-24 2022-11-23 Salk Institute for Biological Studies Oncolytic tumor viruses and methods of use
WO2016057387A1 (en) 2014-10-06 2016-04-14 The Trustees Of The University Of Pennsylvania Compositions and methods for isolation of circulating tumor cells (ctc)
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2016128542A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
WO2016198599A1 (en) * 2015-06-12 2016-12-15 Glaxosmithkline Biologicals S.A. Adenovirus polynucleotides and polypeptides
WO2017096162A1 (en) * 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
CA3013639A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3458589A4 (en) 2016-05-18 2020-01-01 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING MORBUS HUNTINGTON
MX2018014154A (es) 2016-05-18 2019-05-06 Voyager Therapeutics Inc Polinucleotidos moduladores.
JP2019524162A (ja) 2016-08-18 2019-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア モジュラーＡＡＶ送達システムによるＣＲＩＳＰＲ−Ｃａｓゲノム編集
JP2019531787A (ja) 2016-08-30 2019-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN119491003A (zh) 2017-05-05 2025-02-21 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3687582A4 (en) 2017-09-29 2021-07-14 Voyager Therapeutics, Inc. RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
CN111295391B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
US11459583B2 (en) 2017-10-31 2022-10-04 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
MX2020004488A (es) * 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus y usos de estos.
WO2019086450A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
JP2021523914A (ja) 2018-05-15 2021-09-09 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． パーキンソン病を治療するための組成物および方法
US12060567B2 (en) 2018-06-13 2024-08-13 Voyager Therapeutics, Inc. Engineered untranslated regions (UTR) for AAV production
AU2019304569B2 (en) 2018-07-17 2023-07-06 Helixmith Co., Ltd Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
AU2019310459A1 (en) 2018-07-24 2021-02-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
JP7528066B2 (ja) 2018-09-28 2024-08-05 ボイジャー セラピューティクス インコーポレイテッド 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
US20210348242A1 (en) 2018-10-04 2021-11-11 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
CA3115248A1 (en) 2018-10-05 2020-04-09 Voyager Therapeutics, Inc. Engineered nucleic acid constructs encoding aav production proteins
CN113166781A (zh) 2018-10-15 2021-07-23 沃雅戈治疗公司 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
US20230193315A1 (en) 2019-01-31 2023-06-22 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids
TW202217002A (zh) 2020-07-13 2022-05-01 法商傳斯堅公司 免疫抑制之治療
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
WO2022218997A1 (en) 2021-04-12 2022-10-20 Centre National De La Recherche Scientifique (Cnrs) Novel universal vaccine presenting system
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2025188755A1 (en) 2024-03-04 2025-09-12 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
WO2025226842A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Expression control by drg-expressed mirnas
WO2025226841A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Gene therapy approach for treating disorders associated with tnnt2
WO2026011009A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Compositions and methods for muscle disorders
WO2026011008A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Expression control by skeletal muscle-expressed mirnas

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1364343A1 (ru) 1984-07-13 1988-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Способ получени человеческого лейкоцитарного интерферона альфа-2
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4732683A (en) 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
JPH10507758A (ja) 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
EP0787200B1 (en) 1994-10-28 2005-04-20 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
AU722624B2 (en) 1996-09-06 2000-08-10 Trustees Of The University Of Pennsylvania, The An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
CA2304168A1 (en) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
AU1822499A (en) * 1997-12-12 1999-06-28 Saint Louis University Ctip, a novel protein that interacts with ctbp and uses therefor
AU3097399A (en) 1998-03-20 1999-10-11 Trustees Of The University Of Pennsylvania, The Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6210663B1 (en) 1998-08-20 2001-04-03 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
OA12168A (en) 2000-01-31 2006-05-08 Smithkline Beecham Biolog Vaccine for the prophylactic or therapeutic immunization against HIV.
US6740525B2 (en) 2000-02-09 2004-05-25 Genvec, Inc. Adenoviral capsid containing chimeric protein IX
US7344872B2 (en) * 2001-06-22 2008-03-18 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
IL161584A0 (en) * 2001-11-21 2004-09-27 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
WO2005001103A2 (en) 2003-06-20 2005-01-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
ATE449105T1 (de) * 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
EP1718315A4 (en) 2004-02-06 2008-08-13 Univ Monash HIGH DOSE USE OF SULFATED POLYSACCHARIDES IN SHORT INTERVALS FOR THE TREATMENT OF INFECTIONS
EP1802336B1 (en) 2004-10-14 2011-09-07 Crucell Holland B.V. Malaria prime/boost vaccines
EP1858927A2 (en) 2005-02-12 2007-11-28 ViraNative AB Methods and uses of antibodies in the purification of interferon
KR101451620B1 (ko) * 2005-05-12 2014-10-21 글락소 그룹 리미티드 백신 조성물
DE602007004470D1 (de) 2006-04-28 2010-03-11 Univ Pennsylvania Modifiziertes adenovirus-hexon-protein und anwendungen davon
BRPI0819774A2 (pt) 2007-11-28 2014-10-14 Univ Pennsylvania Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
US8524219B2 (en) * 2007-11-28 2013-09-03 The Trustees Of The University Of Pennsylvania Simian subfamily B adenoviruses SAdV-28, -27, -29, -32, -33, and -35 and uses thereof
PL2220241T3 (pl) 2007-11-28 2017-06-30 The Trustees Of The University Of Pennsylvania Adenowirus zawierający kapsydowe białko heksonu SAdV-39 małpiego adenowirusa E oraz jego zastosowanie
EP2325298B1 (en) 2008-03-04 2016-10-05 The Trustees Of The University Of Pennsylvania SIMIAN ADENOVIRUSES SAdV-36, -42.1, -42.2, AND -44 AND USES THEREOF
US9603035B2 (en) 2011-10-13 2017-03-21 Telefonaktiebolaget L M Ericsson Method and node related to channel estimation

Also Published As

Publication number Publication date
BRPI0819783A2 (pt) 2015-06-23
JP5740158B2 (ja) 2015-06-24
KR20100109915A (ko) 2010-10-11
SG10201604001XA (en) 2016-07-28
KR101614364B1 (ko) 2016-04-22
JP2011522513A (ja) 2011-08-04
AU2008331906A1 (en) 2009-06-11
CN101883858B (zh) 2015-07-22
KR101662574B1 (ko) 2016-10-05
CA2706258A1 (en) 2009-06-11
DK2220241T3 (en) 2017-01-09
HUE032142T2 (en) 2017-08-28
US20140155476A1 (en) 2014-06-05
KR20150108945A (ko) 2015-09-30
US20100247490A1 (en) 2010-09-30
CN101883858A (zh) 2010-11-10
JP2016195595A (ja) 2016-11-24
KR20160118370A (ko) 2016-10-11
CY1118351T1 (el) 2017-06-28
JP2015083006A (ja) 2015-04-30
US9359618B2 (en) 2016-06-07
WO2009073104A3 (en) 2009-08-20
ES2607029T3 (es) 2017-03-28
CA2706258C (en) 2017-06-06
SI2220241T1 (sl) 2017-02-28
MX347246B (es) 2017-04-19
EP2220241B1 (en) 2016-09-14
EP2220241A2 (en) 2010-08-25
HRP20161573T1 (hr) 2017-02-10
KR101761691B1 (ko) 2017-07-26
US8685387B2 (en) 2014-04-01
AU2008331906B2 (en) 2014-03-06
WO2009073104A2 (en) 2009-06-11
JP6224769B2 (ja) 2017-11-01
WO2009073104A8 (en) 2016-03-31
PT2220241T (pt) 2016-12-26
CA2964396A1 (en) 2009-06-11
EP3128010A1 (en) 2017-02-08
PL2220241T3 (pl) 2017-06-30
US20160244783A1 (en) 2016-08-25
LT2220241T (lt) 2016-12-12

Similar Documents

Publication Publication Date Title
MX347246B (es) Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.
MX2010005860A (es) Adenovirus simianos de la subfamilia c sadv-40, sadv-31 y sadv-34 y usos de los mismos.
WO2009136977A3 (en) Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
WO2012071318A3 (en) Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
MX344106B (es) Adenovirus simianos de la subfamilia b sadv-28, sadv-29, sadv-32, sadv-33 y sadv-35 y usos de los mismos.
MX2014014024A (es) Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.
SG165153A1 (en) Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
DK2012822T3 (da) Modificeret adenovirushexonprotein og anvendelser deraf
EP3950947A4 (en) NEW RECOMBINANT CORONAVIRUS VACCINE USING REPLICATION DEFICIENT HUMAN ADENOVIRUS AS A VECTOR
NZ594355A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
BR112014008167A2 (pt) affenadenovirus (gorilla) ou vetores adenovirais e métodos de uso
CL2011002913A1 (es) Plasmido novedoso con numero de acceso mtcc 5561; virus de vaccinia ankara modificado (mva) recombinante.
EP1771570A4 (en) ADDITION OF TRANSGENES IN ADENOVIRUS VECTORS
MX2019006725A (es) Polinucleotidos y polipeptidos de adenovirus.
BR112014008249A2 (pt) affenadenovirus (gorilla) ou vetores adenovirais e métodos de uso
MX2019008921A (es) Adenovirus recombinante de transgenes múltiples.
UA106733C2 (uk) Вектор експресії
WO2007134325A3 (en) Methods and compositions for protein production using adenoviral vectors
WO2007087478A3 (en) Linear vectors, host cells and cloning methods
MX2020013553A (es) Polinucleotidos y polipeptidos de adenovirus.
DK1498129T3 (da) Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling
MX2018000353A (es) Sistema vector de adenovirus aviar 9 (fadv-9) y metodos asociados.
WO2008095168A3 (en) Compositions and methods related to a recombinant adenoviral vector that targets il 13 receptors
WO2006008468A3 (en) Adenovirus vector and method to manipulate the adenovirus genome
EP2085475A4 (en) METHOD FOR THE PRODUCTION OF A CELL STAMM WITH ABILITY FOR TETRACYCLIN-INDUCED GENE EXPRESSION OR A CELL STEM WITH CONDITIONAL GENE KNOCKOUT AND USE OF THE CELL STRAINS

Legal Events

Date Code Title Description
FG Grant or registration